P276-00 is primarily used in the pharmaceutical industry as a potent inhibitor targeting specific proteins involved in cancer progression. It is particularly effective in inhibiting cyclin-dependent kinases (CDKs), which play a crucial role in cell cycle regulation. By blocking these kinases, P276-00 helps in arresting the growth of cancer cells, making it a valuable candidate for cancer therapy, especially in cases of breast cancer, lung cancer, and melanoma. Additionally, it has shown promise in enhancing the efficacy of other chemotherapy agents when used in combination therapies. Research is ongoing to explore its potential in treating other CDK-related diseases and its role in improving patient outcomes in oncology.